Search

Your search keyword '"Fornarini, G."' showing total 346 results
Start Over Author "Fornarini, G."
346 results on '"Fornarini, G."'

1. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Author

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., Mastracci, L., Grillo, F., Cabiddu, F., Guadagno, A., Coco, S., Allavena, E., Barbero, F., Bruno, W., Dalmasso, B., Bellomo, S. E., Marchiò, C., Spagnolo, F., Sciallero, S., Berrino, E., and Ghiorzo, P.

Published
2024
Full Text
View/download PDF

3. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study

Author

Internò, V., Massari, F., Rudà, R., Maiorano, B.A., Caffo, O., Procopio, G., Bracarda, S., Atzori, F., Passarelli, A., Bersanelli, M., Stellato, M., Fornarini, G., Galli, L., Ortega, C., Zanardi, E., Incorvaia, L., Facchini, G., Giron Berrios, J.R., Ricotta, R., Santoni, M., Funaioli, C., Trerotoli, P., Porta, C., and Rizzo, M.

Published
2023
Full Text
View/download PDF

4. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Author

Rebuzzi, S.E., Signori, A., Buti, S., Banna, G.L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, F., Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, A., Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., and Fornarini, G.

Published
2022
Full Text
View/download PDF

5. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Author

Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., and Sternberg, C.N.

Published
2021
Full Text
View/download PDF

7. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Author

Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Carella, C., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Merler, S., additional, Masini, C., additional, De Vivo, R., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional

Published
2022
Full Text
View/download PDF

8. 1305P Landscape and clinical significance of germline pathogenic variants (PV) in pancreatic cancer (PC)-predisposing genes in PC patients

Author

Gandini, A., primary, Pastorino, L., additional, Ponzano, M., additional, Puglisi, S., additional, Borea, R., additional, Cremante, M., additional, Grassi, M., additional, Bruno, W., additional, Dalmasso, B., additional, Andreotti, V., additional, Vanni, I., additional, Allavena, E., additional, Catalano, F., additional, Martelli, V., additional, Pastorino, A., additional, Iaia, M.L., additional, Fornarini, G., additional, Sciallero, M.S., additional, Puccini, A., additional, and Ghiorzo, P., additional

Published
2022
Full Text
View/download PDF

9. 445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state

Author

Pastorino, A., primary, Puccini, A., additional, Martelli, V., additional, Grassi, M., additional, Cremante, M., additional, Gandini, A., additional, Puglisi, S., additional, Catalano, F., additional, Murianni, V., additional, Pessino, A., additional, Andretta, V., additional, Mammoliti, S., additional, Sciallero, M.S., additional, Comandini, D., additional, Fornarini, G., additional, Caprioni, F., additional, Bregni, G., additional, Barni, S., additional, Labianca, R., additional, and Sobrero, A.F., additional

Published
2022
Full Text
View/download PDF

10. 1469P Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)

Author

Guida, A., primary, Maruzzo, M., additional, Lai, E., additional, Bimbatti, D., additional, Pierantoni, F., additional, Dionese, M., additional, Caserta, C., additional, Mosillo, C., additional, Calandrella, M.L., additional, Macrini, S., additional, Fornarini, G., additional, Zanardi, E., additional, Damassi, A., additional, Calabrò, F., additional, Cerbone, L., additional, Astore, S., additional, Galli, L., additional, and Bracarda, S., additional

Published
2022
Full Text
View/download PDF

11. 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Author

Rebuzzi, S.E., primary, Rescigno, P., additional, Signori, A., additional, Brunelli, M., additional, Galuppini, F., additional, Vellone, V.G., additional, Gaggero, G., additional, Maruzzo, M., additional, Milella, M., additional, Vignani, F., additional, Cavo, A., additional, Basso, U., additional, Catalano, F., additional, Murianni, V., additional, Cremante, M., additional, Damassi, A., additional, Llaja Obispo, M.A., additional, Banna, G.L., additional, Buti, S., additional, and Fornarini, G., additional

Published
2022
Full Text
View/download PDF

12. LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

Author

Ciccarese, C., Porcari, S., Buti, S., Fornarini, G., Primi, F., Giudice, G.C., Damassi, A., Giron Berrios, J.R., Stumbo, L., Arduini, D., Severino, A., Rondinella, D., Masucci, L., Sanguinetti, M., Gasbarrini, A., Cammarota, G., Segata, N., Tortora, G., Ianiro, G., and Iacovelli, R.

Published
2024
Full Text
View/download PDF

13. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

14. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

15. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Author

Basso, U., Paolieri, F., Rizzo, M., De Giorgi, U., Bracarda, S., Antonuzzo, L., Atzori, F., Cartenì, G., Procopio, G., Fratino, L., D’Arcangelo, M., Fornarini, G., Zucali, P., Cusmai, A., Santoni, M., Pipitone, S., Carella, C., Panni, S., Deppieri, F. M., Zagonel, V., and Tortora, Giampaolo

Subjects
Settore MED/06 - ONCOLOGIA MEDICA, cancer
Abstract

This is a retrospective analysis on the safety and activity of compassionate Ipilimumab and Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as a first-line regimen. IPI was infused at 1 mg/kg in combination with Nivolumab 3 mg/kg every three weeks for four doses, followed by maintenance Nivolumab (240 or 480 mg flat dose every two or four weeks, respectively) until disease progression or unacceptable toxicity. A total of 324 patients started IPI-NIVO at 86 Italian centers. Median age was 62 years, 68.2% IMDC intermediate risk. Primary tumor had been removed in 65.1% of patients. Two hundred and twenty patients (67.9%) completed the four IPI-NIVO doses. Investigator-assessed overall response rate was 37.6% (2.8% complete). Twelve-month survival rate was 66.8%, median progression-free survival was 8.3 months. Grade 3 or 4 treatment-related adverse events occurred in 67 patients (26.9%). IMDC intermediate risk, nephrectomy, BMI ≥ 25 kg/m

Published
2022

16. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Author

Rebuzzi, S. E., Signori, A., Buti, S., Banna, G. L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, Diana, Tortora, Giampaolo, Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, Francesco, Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, Antonio, Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G., Giannarelli D., Tortora G. (ORCID:0000-0002-1378-4962), Atzori F., Astone A. (ORCID:0000-0001-9572-309X), Rebuzzi, S. E., Signori, A., Buti, S., Banna, G. L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, Diana, Tortora, Giampaolo, Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, Francesco, Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, Antonio, Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G., Giannarelli D., Tortora G. (ORCID:0000-0002-1378-4962), Atzori F., and Astone A. (ORCID:0000-0001-9572-309X)

Abstract

Background: The Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated metastatic renal cell carcinoma (mRCC) by adding the pre-treatment neutrophil-to-lymphocyte ratio and presence of bone metastases.Materials and methods: A post hoc analysis was carried out to validate the Meet-URO score on the overall survival (OS) of patients with IMDC intermediate-poor-risk mRCC treated with first-line nivolumab plus ipilimumab within the prospective Italian Expanded Access Programme (EAP). We additionally considered progression-free survival (PFS) and disease response rates. Harrell's c-index was calculated to compare the accuracy of survival prediction.Results: Overall the EAP included 306 patients, with a median follow-up of 12.2 months, median OS was not reached, 1-year OS was 66.8% and median PFS was 7.9 months. By univariable analysis, both the IMDC score and the two additional variables of the Meet-URO score were associated with either OS or PFS (P < 0.001 for all comparisons). The four Meet-URO risk groups (G) had 1-year OS of 92%, 72%, 50% and 21% for G2 (29.1% of patients), G3 (28.8%), G4 (33.0%) and G5 (9.1%), respectively. OS was significantly shorter in each consecutive G (P = 0.001 for G3, P < 0.001 for both G4 and G5 compared to G2). Similarly, Meet-URO Gs 2-5 showed decreasing median PFS and response rates. The Meet-URO score showed the highest c-index for both OS (0.73) and PFS (0.67). Limitations include the post hoc nature of this analysis and the lack of a comparative arm to assess predictive value.Conclusion: The Meet-URO score appeared to show better prognostic classification than the IMDC alone in patients with mRCC at IMDC intermediate-poor risk treated with first-line nivolumab and ipilimumab.

Published
2022

17. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Author

Iacovelli, Roberto R, Ciccarese, C, Brunelli, M, Battelli, N, Buttigliero, C, Caserta, C, Buti, S, Santini, D, Carella, C, Galli, L, Verri, E, Ermacora, P, Merler, S, Masini, C, De Vivo, R, Milesi, L, Spina, F, Rizzo, M, Sperduti, I, Fornarini, G, and Tortora, G

Subjects
PD-L1, Carcinoma, Transitional Cell, biomarkers, Hematology, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, cisplatin ineligible, Urinary Bladder Neoplasms, Oncology, Humans, bladder cancer, avelumab, immunotherapy, Cisplatin, Aged
Abstract

Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC.Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan-Meier product-limit methodology and compared across groups using the log-rank test.A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patients were alive at 1 year. A complete response was achieved in 8.5% of cases, and 15.5% had a partial response. Adverse any-grade and high-grade events occurred in 49.3% and 8.5% of patients, respectively. A grade 3 infusion reaction was the only high-grade treatment-related adverse event. No treatment-related deaths were reported.This ARIES trial confirmed the activity and safety of avelumab for treating mUC, adding a new therapy option to the armamentarium of checkpoint inhibitors already approved for platinum-ineligible, locally advanced/mUC.

Published
2022

20. First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

Author

Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Naglieri, E., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Milella, M., additional, Masini, C., additional, Aprile, G., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional

Published
2022
Full Text
View/download PDF

22. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab

Author

De Giorgi, U, Procopio, G, Giannarelli, D, Sabbatini, R, Bearz, A, Buti, S, Basso, U, Mitterer, M, Ortega, C, Bidoli, P, Ferraù, F, Crinò, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Fornarini, G, Cartenì, G, Caserta, C, Sternberg, C, De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN., De Giorgi, U, Procopio, G, Giannarelli, D, Sabbatini, R, Bearz, A, Buti, S, Basso, U, Mitterer, M, Ortega, C, Bidoli, P, Ferraù, F, Crinò, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Fornarini, G, Cartenì, G, Caserta, C, Sternberg, C, De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, and Sternberg CN.

Abstract

Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

Published
2019

23. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

Author

De Giorgi, U, Cartenì, G, Giannarelli, D, Basso, U, Galli, L, Cortesi, E, Caserta, C, Pignata, S, Sabbatini, R, Bearz, A, Buti, S, Lo Re, G, Berruti, A, Bracarda, S, Cognetti, F, Rastelli, F, Fornarini, G, Porta, C, Turci, D, Sternberg, C, Procopio, G, Bidoli, P, De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G, Bidoli P, De Giorgi, U, Cartenì, G, Giannarelli, D, Basso, U, Galli, L, Cortesi, E, Caserta, C, Pignata, S, Sabbatini, R, Bearz, A, Buti, S, Lo Re, G, Berruti, A, Bracarda, S, Cognetti, F, Rastelli, F, Fornarini, G, Porta, C, Turci, D, Sternberg, C, Procopio, G, Bidoli, P, De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G, and Bidoli P

Abstract

Objective: To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods: Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. Patients included in the analysis had received ≥1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Results: A total of 389 patients were enrolled between July 2015 and April 2016, of whom 18% were aged ≥75 years, 6.7% had non-clear cell RCC, 49.6% had bone and 8.2% brain metastases, and 79% had received ≥2 previous lines of therapy. The most common any-grade treatment-related AEs were fatigue (13%) and rash (9%). Twenty-two patients (5.7%) discontinued treatment because of AEs. There were no treatment-related deaths. The objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% confidence interval 3.7–6.2) and the 12-month overall survival rate was 63%. Similar survival rates were reported among patients with non-clear-cell histology, elderly patients, those with bone and/or brain metastases, and those who had received prior first-line sunitinib or pazopanib, or prior everolimus. Conclusion: The safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non-clear-cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patients. © 2018 The Authors BJU International

Published
2019

24. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

Background: No compelling evidence is available about surveillance and follow-up of patients with testicular germ cell tumour (TGCT). Methods: In the light of the best clinical evidence, the Italian Germ cell cancer Group (IGG) and the Associazione Italiana di Oncologia Medica (AIOM) set up a multidisciplinary national consensus conference, involving 42 leading experts and 3 TGCT survivors. A minimum of 50% of votes was required in order to achieve a consensus recommendation on 29 questions. Results: Recommendations have been summarized in three tables, divided by stage I seminoma, stage I nonseminoma and the advanced disease, which may be useful for clinicians to appropriately choose the clinical investigation and its timing during the surveillance and follow-up of TGCT patients based on an accurate estimation of their risk of disease relapse. Conclusions: The IGG-AIOM consensus recommendations may help clinicians to choose appropriate clinical investigations for the surveillance and follow-up of TGCT patients.

Published
2019

26. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma

Author

Del Re, M., primary, Brighi, N., additional, Rizzo, M., additional, Paolieri, F., additional, Rebuzzi, S.E., additional, Beninato, T., additional, Crucitta, S., additional, Mercinelli, C., additional, Gri, N., additional, Puglisi, S., additional, Verzoni, E., additional, Bleve, S., additional, Cucchiara, F., additional, Procopio, G., additional, Fornarini, G., additional, Galli, L., additional, Porta, C.G., additional, De Giorgi, U., additional, and Danesi, R., additional

Published
2021
Full Text
View/download PDF

27. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

Author

Rebuzzi, S.E., primary, Signori, A., additional, Maruzzo, M., additional, Tortora, G., additional, Galli, L., additional, Rizzo, M., additional, De Giorgi, U., additional, Antonuzzo, L., additional, Bracarda, S., additional, Cartenì, G., additional, Atzori, F., additional, Tamberi, S., additional, Procopio, G., additional, Fratino, L., additional, Santoni, M., additional, Baldessari, C., additional, Astone, A., additional, Calabro', F., additional, Buti, S., additional, and Fornarini, G., additional

Published
2021
Full Text
View/download PDF

28. 615P Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)

Author

Gurioli, G., primary, Conteduca, V., additional, Brighi, N., additional, Scarpi, E., additional, Basso, U., additional, Fornarini, G., additional, Mosca, A., additional, Nicodemo, M., additional, Banna, G.L., additional, Lolli, C., additional, Schepisi, G., additional, Ravaglia, G., additional, Ulivi, P., additional, and De Giorgi, U., additional

Published
2021
Full Text
View/download PDF

31. 1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

Author

Rebuzzi, S.E., Signori, A., Buti, S., Maruzzo, M., De Giorgi, U.F.F., Zucali, P.A., Procopio, G., Fratino, L., Pipitone, S., Mollica, V., Soraru, M., Chiellino, S., Lipari, H., Galli, L., Masini, C., Naglieri, E., Milella, M., Ricotta, R., Banna, G.L., and Fornarini, G.

Published
2023
Full Text
View/download PDF

32. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Author

Powles, T.B., Perez Valderrama, B., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S.H., Shin, S.J., Castellano Gauna, D.E., Fornarini, G., Li, J-R., Gumus, M., Mar, N., Narayanan, S., Yu, X., Gorla, S., and Homet Moreno van der Heijden, B.M.S.

Published
2023
Full Text
View/download PDF

33. 1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial

Author

Brighi, N., Wetterskog, D., Gurioli, G., Orlando, F., Conteduca, V., Casadei, C., Lolli, C., Giunta, E.F., Bleve, S., Vainauskas, O., Basso, U., Pierantoni, F., Fornarini, G., Mosca, A., Nicodemo, M., Banna, G.L., Ulivi, P., Demichelis, F., De Giorgi, U.F.F., and Attard, G.

Published
2023
Full Text
View/download PDF

35. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Author

Caffo, O., primary, Zagonel, V., additional, Baldessari, C., additional, Berruti, A., additional, Bortolus, R., additional, Buti, S., additional, Ceresoli, G.L., additional, Donini, M., additional, Ermacora, P., additional, Fornarini, G., additional, Fratino, L., additional, Masini, C., additional, Massari, F., additional, Mosca, A., additional, Mucciarini, C., additional, Procopio, G., additional, Tucci, M., additional, Verri, E., additional, Zucali, P., additional, and Buttigliero, C., additional

Published
2020
Full Text
View/download PDF

36. 802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study

Author

Brunelli, M., primary, Buti, S., additional, Rebuzzi, S.E., additional, Milella, M., additional, Vellone, V., additional, Bersanelli, M., additional, Maruzzo, M., additional, Basso, U., additional, Signori, A., additional, Martelli, V., additional, Catalano, F., additional, Damassi, A., additional, Murianni, V., additional, Merler, S., additional, Casartelli, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

37. 767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Banna, G.L., additional, Ermacora, P., additional, Morelli, F., additional, Nolè, F., additional, Marandino, L., additional, Panni, S., additional, Massari, F., additional, Hamzaj, A., additional, Milesi, L., additional, Santini, D., additional, De Tursi, M., additional, Scartozzi, M., additional, Astolfi, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

38. 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study

Author

Basso, U., primary, Paolieri, F., additional, Porta, C.G., additional, De Giorgi, U., additional, Bracarda, S., additional, Antonuzzo, L., additional, Atzori, F., additional, Cartenì, G., additional, Procopio, G., additional, Fratino, L., additional, D'Arcangelo, M., additional, Fornarini, G., additional, Zucali, P.A., additional, Cusmai, A., additional, Santoni, M., additional, Baldessari, C., additional, Naglieri, E., additional, Panni, S., additional, Zagonel, V., additional, and Tortora, G., additional

Published
2020
Full Text
View/download PDF

39. 768P Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Fornarini, G., additional, Calabro', F., additional, Baldessari, C., additional, Scandurra, G., additional, De Giorgi, U., additional, Masini, C., additional, Naglieri, E., additional, Caserta, C., additional, Galli, L., additional, Maruzzo, M., additional, Zampiva, I., additional, Buttigliero, C., additional, Astolfi, C., additional, and Banna, G.L., additional

Published
2020
Full Text
View/download PDF

44. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Author

Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, Schinzari Giovanni (ORCID:0000-0001-6105-7252), Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, and Schinzari Giovanni (ORCID:0000-0001-6105-7252)

Abstract

AIM: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. METHODS: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. RESULTS: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001. CONCLUSION: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.

Published
2018

45. Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Author

Michele, P., primary, Ratta, R., additional, Iacovelli, R., additional, Mancini, M., additional, Fornarini, G., additional, Facchini, G., additional, Cartenì, G., additional, Napolitano, M., additional, Del Bene, G., additional, Santini, D., additional, Mariella Sorarù, M., additional, Vitale, M.G., additional, Ricotta, R., additional, Tucci, M., additional, Luzi Fedeli, S., additional, Boe, M.G., additional, Mecozzi, A., additional, Ortega, C., additional, Stemberg, C.N., additional, and Procopio, G., additional

Published
2017
Full Text
View/download PDF

47. Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Author

Procopio, G., primary, Prisciandaro, M., additional, Iacovelli, R., additional, Mancini, M., additional, Fornarini, G., additional, Facchini, G., additional, Cartenì, G., additional, Napolitano, M., additional, Sternberg, C.N., additional, Caserta, C., additional, Bregni, M., additional, Massari, F., additional, Buti, S., additional, Biasco, E., additional, De Giorgi, U., additional, Zustovich, F., additional, Ratta, R., additional, Ortega, C., additional, Tortora, G., additional, and Verzoni, E., additional

Published
2017
Full Text
View/download PDF

48. Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)

Author

De Giorgi, U., primary, Procopio, G., additional, Guida, A., additional, Bearz, A., additional, Buti, S., additional, Basso, U., additional, Mitterer, M., additional, Ortega, C., additional, Bidoli, P., additional, Ferrau, F., additional, Crinò, L., additional, Frassoldati, A., additional, Marchetti, P., additional, Mini, E., additional, Scoppola, A., additional, Verusio, C., additional, Fornarini, G., additional, Cartenì, G., additional, Caserta, C., additional, and Sternberg, C.N., additional

Published
2017
Full Text
View/download PDF

50. Probiotics in IBD: A critical review

Author

GIONCHETTI, PAOLO, CALABRESE, CARLO, TAMBASCO, ROSY, STRAFORINI, GIULIA, BRUGNERA, RAMONA, LIGUORI, GIUSEPPINA, RIZZELLO, FERNANDO, Spuri Fornarini G, Gionchetti P, Calabrese C, Tambasco R, Straforini G, Brugnera R, Spuri Fornarini G, Liguori G, and Rizzello F

Subjects
IBD, Probiotics, digestive system, digestive system diseases
Abstract

The rationale underlying probiotics use in the treatment of IBD is based on compelling evidence that intestinal bacteria have a role in disease pathogenesis. The distal ileum and the colon are the areas with the highest bacterial concentrations and are also the sites of inflammation in IBD. Similarly, pouchitis, the nonspecific inflammation of the ileal reservoir that can occur after ileo-anal anastomosis, appears to be associated with bacterial overgrowth and dysbiosis. Enteric bacteria and their products have also been found within the inflamed mucosa of patients with Crohn’s disease

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results